Citi analyst Tyler Radke raised the firm’s price target on Veeva Systems to $240 from $236 and keeps a Buy rating on the shares. With concerns around the broader biopharma demand environment and Vault migration, the company’s Q2 results were better than feared with a solid billings beat, a reiteration of full year revenue targets and slight raise to profitability, the analyst tells investors in a research note. The firm believes Veeva’s business is more resilient to the macro environment versus peers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VEEV:
- Veeva Systems (NYSE:VEEV): Here’s How Analysts Reacted to the Stock After Q2 Results
- Veeva price target raised to $227 from $225 at Barclays
- Veeva price target raised to $220 from $200 at BofA
- Veeva price target raised to $211 from $205 at Stifel
- Veeva price target raised to $240 from $210 at Raymond James